Podcasts about Lung cancer

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Elene Mariamidze moderates a discussion in Georgian about highlights from the conference with Dr. Salome Begijanashvili, Dr. Beka Shubitidze, and Dr. Mariam Tchiabrishvili.

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer. Episode Highlights: MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach. FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with chemotherapy for EGFR-positive NSCLC. SOHO-01 & Beamion LUNG-1: emerging HER2-positive NSCLC treatments, Zongertinib and Sevabertinib. Discussion on the significance of NGS testing in identifying mutations and tailoring treatment options for patients. Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care.  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on practice-changing research and major conference highlights! #ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers

In this podcast, we review a comparison of outcomes in patients 65-74 years old from SEER-Medicare and NLST datasets in stage I lung cancer with study first author, Dr. Nichole Tanner as well as Dr. Neal Navani.

Drs. Cooper and Rotow review the challenges of CNS involvement in HER2+ NSCLC, emphasizing the importance of baseline and ongoing brain imaging, and the emerging understanding of CNS penetrance for HER2-targeted therapies. They explore strategies for managing brain metastases, including balancing local therapies, including radiation with systemic treatments, and highlight the need for multidisciplinary approaches and further research on CNS activity in clinical trials.

X101's Matt Brooks speaks with Courtney Maxson, Senior Public Health Educator from the Cortland County Health Department. In addition to talking Lung Cancer Awareness Month, Courtney encourages all to get[Read More...] The post November is Lung Cancer Awareness Month, and Radon is a Leading Cause of Lung Cancer in Cortland County appeared first on X101 Always Classic - WXHC.com.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez speaks with two remarkable young lung cancer advocates Samantha Murell and Megan Flanagan, who are redefining what it means to live with the disease. They share their journeys from diagnosis to advocacy, shedding light on the challenges young patients face, breaking misconceptions, and offering hope to others along the way.

Drs. Rotow and Cooper explore the evolving landscape of HER2+ NSCLC treatment, highlighting recent advancements in targeted therapies like HER2 TKIs and antibody-drug conjugates. They emphasize the importance of comprehensive biomarker testing, the significance of personalized treatment approaches, and the exciting progress in providing more effective and tolerable second-line therapies for patients. The discussion underscores the field's movement toward precision medicine and the potential for future combination strategies and improved patient outcomes.

Drs. Cooper and Rotow discuss first-line treatment strategies for HER2+ NSCLC, highlighting the importance of comprehensive molecular testing and emerging targeted therapies. Key considerations include the efficacy of antibody-drug conjugates and TKIs, with ongoing clinical trials evaluating their potential as frontline treatments. The discussion emphasizes the need for personalized treatment approaches based on individual patient characteristics, molecular features, and the evolving landscape of HER2-targeted therapies.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Zsolt Megyesfalvi moderates a discussion in Hungarian about highlights from the conference with Dr. Zsuzsanna Keleman, Dr. Lilla Horvath, and Dr. Gyula Ostoros.

I recently had an ApoB test and am surprised that it isn't lower than it is.  Can you explain?I have an ascending thoracic aortic aneurysm.  How can I keep it from enlarging?Why are you against whole-body scans? Aren't they helpful?Can I take magnesium L-threonate while also taking magnesium glycinate?

Will Truheight vitamins really make your kids grow?Where can I learn more about complementary medicine and nutrition?The balls of my feet are sore along with my toes. Is this a vitamin deficiency?

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by: Thomas Bauer, MD, the chair of surgery at Jersey Shore University Medical Center in Neptune Township, New Jersey, and Hackensack Meridian Health School of Medicine Rachel NeMoyer, MD, a thoracic surgeon at Hackensack Meridian Health Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence. They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational. They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

In this episode of Thinking Thoracic, host Dr. Erin Gillaspie talks with Dr. Robert Lentz and Dr. Fabien Maldonado about the groundbreaking VERITAS trial, which is reshaping how clinicians diagnose lung cancer. Published in the New England Journal of Medicine, the VERITAS trial compared navigational bronchoscopy with CT-guided biopsy in a rigorous, randomized design, bringing much-needed evidence to interventional pulmonology. The discussion explores how the study was conceived, why robust device trials are vital to patient outcomes, and what the findings mean for the future of minimally invasive lung diagnostics.

Evening prayer (people with lung cancer, people in abusive circumstances)#pray #prayer #eveningprayer #jesus #lungcancer #abuse #abusive #help #hope #healing Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

A Colorado doctor was diagnosed with the same lung cancer he's researched and treated all his life. He only recently decided to share his story when chemotherapy made him horribly sick. Dr. Ross Camidge talks about sharing the same path as his patients, and how he views death and what comes next. Then, from artwork to hidden history on the walls, Purplish explores the many stories the state capitol has to tell. Plus, just in time for Halloween, a Colorado haunting... and a reimagining of Ichabod Crane. 

Riverside Healthcare Imaging Patient Navigator Maureen Elliott discusses what to expect from a CT lung cancer screening and who should schedule an appointment.

This episode of Lung Cancer Considered covers highlights from the 2025 ESMO Annual Meeting held October 17th to the 21st in Berlin, Germany. Guests are: Dr. Xiuning Le from MD Anderson Cancer Center in Houston, Texas. Dr. Pedro Rocha from Vall d'Hebron University Hospital in Barcelona, Spain. Dr. Riyaz Shah, a consultant medical oncologist at the Kent Oncology Centre in the United Kingdom.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Early detection saves lives, but today's tools are often invasive, slow, or used too late. In this episode, Breath Diagnostics CEO Ivan Lo explains how a non-invasive breath test can detect volatile organic compounds (VOCs) associated with disease—positioning breath as a first-line screen for early-stage lung cancer and potentially pneumonia and TB. We cover the science (why breath can capture near real-time biological change), sensitivity/specificity signals from 800+ patients, and a go-to-market/regulatory plan that prioritizes post-op pneumonia (shorter trials, no entrenched standard of care) before lung cancer screening. We also discuss platform economics (low-cost disposables, existing LC-MS infrastructure), trial scale and cost, and how breath could support ongoing monitoring after treatment. Investors get a clear view of timelines, risks, and upside; founders get lessons on platform positioning, capital efficiency, and sequencing indications. Highlights include...Why breath (VOCs) can surface disease signals minutes–hours after biological changeFirst-line screening thesis vs. liquid biopsy and CT workflowsEarly data: ~94% sensitivity / 85% specificity across 800+ patients (lung cancer context)Regulatory path: post-op pneumonia first (faster FDA route), lung cancer nextUnit economics: low-cost cartridge + existing LC-MS labs (hub-and-spoke)Clinical design: trial scale, costs, and companion-diagnostic “cocktail” potentialPlatform beyond oncology: pneumonia, TB, inflammation, RUO for pharmaChapters00:00 Intro & why early detection needs a rethink00:47 What Breath Diagnostics does (the “breath bag”)03:34 VOCs 101: why breath can be earlier than blood06:41 First-line screen vs. confirmatory tests08:19 Will this be ubiquitous at annual visits?11:53 Commercialization path & funding realities12:37 Pneumonia first: faster FDA route14:09 Lung cancer timeline & business model15:34 Hospital economics & pneumonia savings18:24 Trial scale/costs; disposable chip economics20:34 Team, funding strategy, and sequencing22:08 Early data and a “false negative” biopsy case24:12 TAM & eligibility (20M Americans qualify)25:06 What success looks like (2–3 years)27:00 Investor closing thoughts

According to the Centers for Disease Control, about 10% to 20% of lung cancers diagnosed in the United State, or 20,000 to 40,000 lung cancers each year, happen in people who never smoked or smoked fewer than 100 cigarettes in their lifetime. Join us as Dr. Alden Maier discusses how this is possible and what nonsmokers should know when it comes to knowing the symptoms and risks for lung cancer.  Learn more about Alden Maier, MD, FACS  

In this episode of Lung Cancer Considered, Dr. Narjust Florez leads a discussion with Ann Fish-Steagall and Amanda Nerstad about the 2025 Lung Cancer Hope Summit. The team discusses highlights from the meeting, including groundbreaking research, innovative treatments, and patient advocacy.

Lung cancer in nonsmoking individuals is increasing worldwide and currently accounts for 15% to 20% of lung cancer cases globally. Benjamin Solomon, PhD, of the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses the epidemiology and treatment of lung cancer in nonsmoking patients with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Lung Cancer in Nonsmoking Individuals ----------------------------------- JAMA Editors' Summary

Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Chi Fu Jeffrey Yang. MD, Thoracic surgeon at Massachusetts General Hospital, Professor of surgery at Harvard Medical School For any cancer patient facing surgery, there are always questions and worries. Hildy interviews an outstanding thoracic surgeon at Massachusetts General Hospital, Chi Fu Jeffrey yang, MD. They discuss the … Continue reading CUT IT OUT! What To Know About Lung Cancer Surgery →

Reasons for nausea  My PSA was 4.0 six months ago, and now it's up to 4.55. What should I do?I have lupus and need to take Methotrexate. How can I protect my liver and immune system?The important relationship between vitamin D3 and K2

How do I keep my LDL low enough without compromising my brain and my liver?I read that fish oil can raise LDL cholesterol. Is this true?A questionable case study on pycnogenol

We explore the leading cause of cancer death worldwide, the relationship with smoking and other risk factors, types of lung cancer, screening in high-risk groups, and advances in treatment. The resource person is Clinical Oncologist, Dr. Nana Ama Wadee.

In this episode, Urologist, Dr. Isaac Asiedu helps us understand the most common cancer in men, PSA testing, symptoms, risk factors, treatment options from active surveillance to surgery, and the impact on quality of life.

Examining the claim that cabbage family vegetables are bad for the thyroid; Walmart announces sweeping move to reformulate its products without synthetic dyes, sketchy additives; Under Congressional questioning, Google admits to censoring contrary narratives on YouTube during Covid; Children garner psychological benefits from grandparent time; J&J fined nearly $1 billion in landmark talc baby powder lawsuit; Humans are among the few animals who can't make their own vitamin C—why that may be a good thing.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Helena Linardou moderates a discussion in Greek about highlights from the conference with Dr. Foteinos-Ioannis Dimitrakopoulos and Dr. Evangelos Sarris.

Lung Cancer Considered: Targeting EGFR NSCLC by IASLC

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Lizza Hendriks moderates a discussion in Dutch with Dr. Marthe Paats and Dr. Gerrina Ruiter on the treatment of EGFR non-small cell lung cancer.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Riad Abdeljalil, Dr. Khaled Abdel Aziz, Dr. Ashraf Abdel Ghani, Dr. Ahmed Rabea, and Dr. Hussein Soudy.

Lung Cancer Considered in Japanese---2025 WCLC Highlights by IASLC

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Min Hee Hong. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Instagram: @fe0120 Guest Name(s) & Title(s): Jeongmin Seo, MD, MSc Assistant Professor, Medical Oncology Seoul National University Bundang Hospital Min Hee Hong, MD Associate Professor, Yonsei Cancer Center Severance Hospital, Seoul

Trials! They come in all sizes and shapes. They're never fun, almost always devastating, and difficult at best. Being diagnosed with Stage 3 Non-Smoker's Lung Cancer in August 2024 was one of the worst trials I've experienced. In James 1, he writes we are to "consider" trials as all joy knowing...." then he continues with why. Crazy? Yes, humanly it is. But through Christ, it is possible because Jesus lives in us and He shows us how He withstood the trial of the cross. In this session you'll learn 4 good things God can bring out of trials that are a part of living in a fallen world. Hold onto your seat and grab a pen to take some notes. Free Listening Guide and James 1:1-12 Video Let's stay social! Follow us on our social media: -Facebook -Instagram -X (Formerly Twitter) -Podbean -Apple Podcasts

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy by IASLC

How does cancer stigma affect well-being? Today we dismantle cancer stigma, look past the diagnosis, and celebrate the person. Find hope, healing, and empowerment in this episode: https://bit.ly/4pN58ryIn this Episode:03:17 - Road Trip to Colorado: Frozen Grandpa and Fool's Gold Sandwich07:34 - Busting the Stigma of a Cancer Diagnosis12:14 - What You Can Do If You Feel Stigmatized After Receiving a Cancer Diagnosis20:08 - What Happens When an Air Passenger Dies During the Flight?24:40 - Outro#cancersurvivor #cancerstigma #morethanadiagnosis #noblame #goodthoughtsforhealing #lungcancer #cervicalcancer #skincancer #lifestyleandcancer #cancerhealing #blamefreezone #everyonedies #everydayisagift Help Us Shatter the StigmaThis podcast is dedicated to dismantling the deep-seated stigma surrounding cancer. Drawing on history and research, we explore why cancer can still be shrouded in fear, blame, and misunderstanding.We go beyond the statistics to reveal the emotional and psychological toll of living with cancer stigma, from social isolation and anxiety to delayed care. We tackle the tough topics—like the unique stigma of lung cancer and other diseases associated with lifestyle choices—and instead celebrate the resilience, empowerment, and hope of cancer survivors.Join us as we reclaim the narrative, offering powerful insights and practical advice for both those diagnosed and the communities that support them. This podcast is a liberating space where your identity is celebrated, and you are seen as more than just a patient.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Howie and Harlan are joined by Kate Heilpern, president of Yale New Haven Hospital, to discuss the innovation and adaption needed to lead NewYork-Presbyterian Hospital through the worst of the COVID-19 pandemic, and how Yale New Haven Health structures itself to provide quality care across five hospitals. Harlan reflects on the many biotech startups emerging from Yale; Howie responds to the Trump administration's assertion of a link between acetaminophen and autism.  Links: Biotech at Yale and Beyond “Investors Flock Back to Biotech After a Long, Cold Spell “Boom, Bust and Recover: What Happens Next as Biotech VC Cycle Resets”. “Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion” Yale Ventures Health & Veritas Ep. 80: Josh Geballe: Turning Yale Innovation into Startups Yale Ventures Annual Report 2025 Cloverleaf Bio Allyx Therapeutics EvolveImmune Therapeutics Normunity Inozyme Pharma “BioMarin to buy rare disease drugmaker Inozyme for $270M” “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018” Kate Heilpern “Yale New Haven Hospital announces new president” “Yale New Haven Health announces Katherine Heilpern, MD, as the new president of Yale New Haven Hospital” “Heilpern sees society reflected in the busy ER” “Meet the Heroes Fighting on the Front Lines Against Covid-19” “'Adrenaline, Duty, and Fear': Inside a New York Hospital Taking on the Coronavirus” Health & Veritas Ep. 116: Christopher O'Connor: Hospital Leadership in Trying Times “Saving America's ERs” “The 600 Pathways Yale New Haven Health Takes to Improved Care Delivery” Tylenol and Autism “Trump Issues Warning Based on Unproven Link Between Tylenol and Autism” “Trump links autism and Tylenol: is there any truth to it?” “Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability” “Study reveals no causal link between neurodevelopmental disorders and acetaminophen exposure before birth” “Does Stress Cause Ulcers?” “The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers” “The U.S. government has jumped the public health shark” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Lung cancer is one of the world's biggest killers. Today, we explore why, and how medical research into this disease is seeing the development of better diagnostic tools, cancer treatments and even a vaccine to prevent tumours from taking hold in the first place... Like this podcast? Please help us by supporting the Naked Scientists

Join us in this episode of the Oncology Brothers podcast as we dive into the highlights from the World Conference on Lung Cancer 2025! We are joined by Dr. Balazs Halmos, a thoracic medical oncologist at the Montefiore Einstein Cancer Center, to discuss three pivotal studies that are shaping the future of lung cancer treatment. In this episode, we covered: •⁠  ⁠FLAURA2 Trial: Discover the significant overall survival benefits of combining osimertinib with chemotherapy for patients with EGFR-positive non-small cell lung cancer, and how it compares to single-agent osimertinib. •⁠  ⁠HARMONi Trial: Explore the intriguing yet complex findings of a new bi-specific antibody targeting PD-1 and VEGF in patients with progressive EGFR-mutated disease, and the implications of its current negative results. •⁠  ⁠ALCHEMIST Trial: Learn about the role of crizotinib in the adjuvant setting for ALK-positive lung cancer and why it reinforces alectinib as the standard of care. Tune in for an insightful discussion on the latest advancements in precision medicine, the importance of ctDNA, and the evolving landscape of lung cancer treatment.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

People who ate the most ultraprocessed foods had a 41% higher risk of developing lung cancer compared with those who ate the least The increased risk was seen in both smokers and nonsmokers, showing that diet alone influences lung cancer development Processed foods alter nutrient absorption, strip away protective compounds, and add toxic byproducts that fuel inflammation and immune dysfunction Harmful chemicals from packaging and high-heat cooking further raise cancer risk and weaken your body's defenses Choosing whole, unprocessed foods and cutting linoleic acid in vegetable oils down to 2 grams or less daily is one of the most effective ways to protect your lungs

The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC. 1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling! 2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of metastatic disease. 4. NEOADAURA tries to determine if neoadjuvant osimertinib has value, but longer follow-up will be needed to assess this practice.

Dr. Halmos from Montefiore in New York shares his views on the most impactful practice changing or informing data for lung cancer from the ASCO 2025 meeting.